Cargando…
Identification of a Novel Subpopulation of Tumor-Initiating Cells from Gemcitabine-Resistant Pancreatic Ductal Adenocarcinoma Patients
Pancreatic ductal adenocarcinoma is highly resistant to systemic chemotherapy. Although there are many reports using pancreatic cancer cells derived from patients who did not receive chemotherapy, characteristics of pancreatic cancer cells from chemotherapy-resistant patients remain unclear. In this...
Autores principales: | Shimizu, Kazuya, Chiba, Sachie, Hori, Yuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836917/ https://www.ncbi.nlm.nih.gov/pubmed/24278411 http://dx.doi.org/10.1371/journal.pone.0081283 |
Ejemplares similares
-
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
por: Nishi, Hidemi, et al.
Publicado: (2023) -
Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Palam, L R, et al.
Publicado: (2015) -
Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018) -
Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
por: Koltai, Tomas, et al.
Publicado: (2022) -
Lipocalin2 Promotes Invasion, Tumorigenicity and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
por: Leung, Lisa, et al.
Publicado: (2012)